- Details
- Description
LuciLaro 100 mg (Larotrectinib) is a targeted anticancer medicine containing larotrectinib, a selective inhibitor of tropomyosin receptor kinase (TRK) proteins. Larotrectinib is designed to target abnormal NTRK gene fusions that can drive the growth and proliferation of cancer cells.
Larotrectinib is used for the treatment of solid tumors that have an NTRK gene fusion, when the cancer is locally advanced, metastatic, or surgical resection is likely to result in severe morbidity, and when there are no satisfactory alternative treatments. Its use is based on confirmed molecular testing and applicable approved indications.
LuciLaro 100 mg is an oral medicine intended for use under the supervision of a qualified healthcare professional. Treatment decisions, dosage, duration, monitoring, and management of potential adverse reactions should be determined according to official prescribing information and the individual patient's clinical condition.
Product strength, packaging, manufacturer, availability, and regulatory status may vary depending on the market and specific product presentation. Healthcare professionals should consult the applicable official product information before prescribing or dispensing this medicine.
